Zachary Junga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zachary Junga has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Amy Stratton
Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, Maryland
1 shared publicationBrett Theeler
Neurology Service, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD
1 shared publication- Christopher Lee Tracy
Womack Army Medical Center Fort Bragg North Carolina
1 shared publication Jeffrey Laczek
Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, Maryland
1 shared publicationManish Singla
Gastroenterology Service, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Md
1 shared publicationMichael Keith
Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 5 (1) , e48
Infliximab-Induced Aseptic Meningitis in a Patient with Crohnʼs Disease
Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.
- 1 January 2018
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 5 (1) , e48
Open AccessInfliximab-Induced Aseptic Meningitis in a Patient with Crohnʼs Disease
Infliximab is an anti-tumor necrosis factor α (TNFα) monoclonal antibody that treats moderate-to-severe Crohn's disease. In rare cases, infliximab has been associated with drug-induced aseptic meningitis. We present a 46-year-old woman with migraines and inflammatory Crohn's colitis treated with intravenous infliximab and methotrexate. She developed nuchal rigidity, photophobia, and headache 2 days after each of her infliximab infusions, with symptom resolution 1 week post-infusion. Her exam, imaging, and cerebrospinal fluid analysis were consistent with drug-induced aseptic meningitis. She discontinued infliximab and started vedolizumab with continued remission of her Crohn's disease.
- 21 August 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus
Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide. She continues to be in remission 1 year following the completion of rituximab infusion and is maintained on hydroxychloroquine. This case highlights the need for further research on the use of rituximab and other available biologics in the setting of MAS in order to help guide further alternative treatment decisions.
- 21 August 2017
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus
Macrophage activation syndrome (MAS) is a rare disease characterised by aberrant immune hyperactivation of T lymphocytes and macrophages driven by cytokine dysfunction. The HLH-2004 protocol is commonly used for the treatment of MAS, but significant toxicities are associated. We describe a case of MAS secondary to systemic lupus erythematosus in a young female that responded well to rituximab in lieu of etoposide. She continues to be in remission 1 year following the completion of rituximab infusion and is maintained on hydroxychloroquine. This case highlights the need for further research on the use of rituximab and other available biologics in the setting of MAS in order to help guide further alternative treatment decisions.
- 1 August 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (8) , A27-A28
Primary Multifocal Small Bowel Follicular Lymphoma Discovered Incidentally on Diagnostic Endoscopy
- 1 August 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (8) , A27-A28
Primary Multifocal Small Bowel Follicular Lymphoma Discovered Incidentally on Diagnostic Endoscopy